PLX
PLX
AMEX · Biotechnology

Protalix Biotherapeutics Inc

$3.03
-0.02 (-0.66%)
Financial Highlights (FY 2026)
Revenue
54.95M
Net Income
-6,881,972
Gross Margin
48.8%
Profit Margin
-12.5%
Rev Growth
+3.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.8% 48.8% 49.5% 49.5%
Operating Margin -10.4% -9.4% 5.5% 5.3%
Profit Margin -12.5% -11.9% 4.3% 3.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 54.95M 53.12M 361.03M 312.42M
Gross Profit 26.83M 25.93M 178.56M 154.52M
Operating Income -5,731,222 -4,986,080 20.00M 16.49M
Net Income -6,881,972 -5,987,215 15.50M 9.93M
Gross Margin 48.8% 48.8% 49.5% 49.5%
Operating Margin -10.4% -9.4% 5.5% 5.3%
Profit Margin -12.5% -11.9% 4.3% 3.2%
Rev Growth +3.5% +3.5% +17.6% +23.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 59.24M 69.52M
Total Equity — — 91.15M 87.27M
D/E Ratio — — 0.65 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,206,104 -3,862,541 29.24M 21.92M
Free Cash Flow — — 6.36M 8.25M